Trevi Therapeutics Stock (NASDAQ:TRVI)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$2.73

52W Range

$0.97 - $4.00

50D Avg

$3.10

200D Avg

$2.91

Market Cap

$223.68M

Avg Vol (3M)

$476.00K

Beta

1.01

Div Yield

-

TRVI Company Profile


Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

27

IPO Date

May 07, 2019

Website

TRVI Performance


TRVI Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income---
Net Income---
EBITDA---
Basic EPS---
Diluted EPS---

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Nov 06, 24 | 11:54 PM
Q2 24Aug 11, 24 | 1:28 AM
Q1 24May 07, 24 | 12:00 AM

Peer Comparison


TickerCompany
GRCLGracell Biotechnologies Inc.
CUECue Biopharma, Inc.
CYTCyteir Therapeutics, Inc.
CGEMCullinan Oncology, Inc.
SEERSeer, Inc.
PRLDPrelude Therapeutics Incorporated
BCABBioAtla, Inc.
FHTXFoghorn Therapeutics Inc.
SPROSpero Therapeutics, Inc.
SQZSQZ Biotechnologies Company
BOLTBolt Biotherapeutics, Inc.
ANTXAN2 Therapeutics, Inc.
ORICORIC Pharmaceuticals, Inc.
CCCCC4 Therapeutics, Inc.
RZLTRezolute, Inc.
ANEBAnebulo Pharmaceuticals, Inc.
TARAProtara Therapeutics, Inc.
NLTXNeurogene Inc.
CHRSCoherus BioSciences, Inc.
LIFEaTyr Pharma, Inc.
LYRALyra Therapeutics, Inc.